[Regulation of fibroblast growth factor 23 in metabolic bone diseases].
Imanishi
Yasuo
Y
Department of Metabolism, Endocrinology and Molecular Medicine, Osaka City University Graduate School of Medicine.
D000818:Animals; D001851:Bone Diseases, Metabolic / Q000235:genetics*; D004195:Disease Models, Animal; D047108:Embryonic Development / Q000235:genetics; D000089703:Fibroblast Growth Factor-23; D005346:Fibroblast Growth Factors / Q000235:genetics* / Q000378:metabolism*; D005357:Fibrous Dysplasia of Bone / Q000235:genetics; D005359:Fibrous Dysplasia, Polyostotic / Q000235:genetics; D018507:Gene Expression Regulation, Developmental / Q000235:genetics*; D006801:Humans; D049950:Hyperparathyroidism, Primary / Q000235:genetics; D007015:Hypophosphatemia, Familial / Q000235:genetics; D008562:Membrane Glycoproteins / Q000235:genetics; D008666:Metalloendopeptidases / Q000235:genetics; D009154:Mutation; D010018:Osteomalacia / Q000235:genetics; D053402:PHEX Phosphate Regulating Neutral Endopeptidase
D008562:Membrane Glycoproteins; D005346:Fibroblast Growth Factors; D000089703:Fibroblast Growth Factor-23; D008666:Metalloendopeptidases; D053402:PHEX Phosphate Regulating Neutral Endopeptidase; C506231:PHEX protein, human